JP2018520102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520102A5 JP2018520102A5 JP2017560254A JP2017560254A JP2018520102A5 JP 2018520102 A5 JP2018520102 A5 JP 2018520102A5 JP 2017560254 A JP2017560254 A JP 2017560254A JP 2017560254 A JP2017560254 A JP 2017560254A JP 2018520102 A5 JP2018520102 A5 JP 2018520102A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- combination according
- dysfunction
- aging
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 230000032683 aging Effects 0.000 claims 13
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 6
- 201000004384 alopecia Diseases 0.000 claims 6
- 229960005167 everolimus Drugs 0.000 claims 6
- 230000003676 hair loss Effects 0.000 claims 6
- 201000010874 syndrome Diseases 0.000 claims 6
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N BEZ235 Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 4
- 206010007554 Cardiac failure Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010057668 Cognitive disease Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 4
- 206010061989 Glomerulosclerosis Diseases 0.000 claims 4
- 206010019280 Heart failure Diseases 0.000 claims 4
- 208000002287 Hemorrhoids Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 210000003491 Skin Anatomy 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 201000001881 impotence Diseases 0.000 claims 4
- 230000002708 enhancing Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 208000009621 Actinic Keratosis Diseases 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010002043 Anaemia folate deficiency Diseases 0.000 claims 2
- 208000007502 Anemia Diseases 0.000 claims 2
- 206010002653 Anosmia Diseases 0.000 claims 2
- 206010003119 Arrhythmia Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 201000011497 Barrett's esophagus Diseases 0.000 claims 2
- 206010004137 Barrett's oesophagus Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 210000004556 Brain Anatomy 0.000 claims 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims 2
- 210000001072 Colon Anatomy 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 241000565118 Cordylophora caspia Species 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 208000005156 Dehydration Diseases 0.000 claims 2
- 208000002925 Dental Caries Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 208000007784 Diverticulitis Diseases 0.000 claims 2
- 208000002173 Dizziness Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010013781 Dry mouth Diseases 0.000 claims 2
- 208000001708 Dupuytren Contracture Diseases 0.000 claims 2
- 208000000059 Dyspnea Diseases 0.000 claims 2
- 206010013975 Dyspnoeas Diseases 0.000 claims 2
- 206010016092 Faecal incontinence Diseases 0.000 claims 2
- 208000001130 Gallstone Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000004559 Hearing Loss Diseases 0.000 claims 2
- 206010011879 Hearing loss Diseases 0.000 claims 2
- 208000002907 Heart Valve Disease Diseases 0.000 claims 2
- 201000001971 Huntington's disease Diseases 0.000 claims 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims 2
- 206010022437 Insomnia Diseases 0.000 claims 2
- 208000001126 Keratosis Diseases 0.000 claims 2
- 208000000913 Kidney Calculi Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 210000003141 Lower Extremity Anatomy 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 206010025135 Lupus erythematosus Diseases 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 210000003205 Muscles Anatomy 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims 2
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000010195 Onychomycosis Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 208000010332 Plantar Fasciitis Diseases 0.000 claims 2
- 208000005987 Polymyositis Diseases 0.000 claims 2
- 206010061529 Polyp Diseases 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims 2
- 208000007932 Progeria Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000009269 Pulmonary Emphysema Diseases 0.000 claims 2
- 206010038436 Renal failure acute Diseases 0.000 claims 2
- 206010038444 Renal failure chronic Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010072736 Rheumatic disease Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 210000000513 Rotator Cuff Anatomy 0.000 claims 2
- 206010039792 Seborrhoea Diseases 0.000 claims 2
- 206010040799 Skin atrophy Diseases 0.000 claims 2
- 206010040984 Sleep disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims 2
- 208000002459 Tendon Injury Diseases 0.000 claims 2
- 206010043248 Tendon rupture Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 210000002435 Tendons Anatomy 0.000 claims 2
- 208000002240 Tennis Elbow Diseases 0.000 claims 2
- 206010043709 Thyroid disease Diseases 0.000 claims 2
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 206010044390 Transient ischaemic attack Diseases 0.000 claims 2
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims 2
- 210000003932 Urinary Bladder Anatomy 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 206010046577 Urinary tract infection Diseases 0.000 claims 2
- 201000011032 Werner syndrome Diseases 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 201000005661 acute cystitis Diseases 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive Effects 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 201000001883 cholelithiasis Diseases 0.000 claims 2
- 201000007368 coagulation protein disease Diseases 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 230000003247 decreasing Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- 201000010046 dilated cardiomyopathy Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000011275 epicondylitis Diseases 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 201000008909 folic acid deficiency anemia Diseases 0.000 claims 2
- 201000011240 frontotemporal dementia Diseases 0.000 claims 2
- 201000005569 gout Diseases 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 2
- 230000003907 kidney function Effects 0.000 claims 2
- 201000004044 liver cirrhosis Diseases 0.000 claims 2
- 201000009673 liver disease Diseases 0.000 claims 2
- 230000004065 mitochondrial dysfunctions Effects 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 201000009925 nephrosclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000008838 periodontal disease Diseases 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 201000010041 presbyopia Diseases 0.000 claims 2
- 201000007737 retinal degeneration Diseases 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 230000000552 rheumatic Effects 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 238000004904 shortening Methods 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 200000000009 stenosis Diseases 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 201000004810 vascular dementia Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001771 impaired Effects 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (20)
- 被験体における免疫応答の増強または促進のために同時、別個または逐次的に使用するための、（ａ）ＲＡＤ００１または薬学的に許容されるその塩、および（ｂ）ＢＥＺ２３５または薬学的に許容されるその塩を含む、組合せ物。
- ＲＡＤ００１が中性形態である、請求項１に記載の組合せ物。
- ＢＥＺ２３５がモノトシル酸塩である、請求項１または２に記載の組合せ物。
- ０．０１〜０．２ｍｇのＲＡＤ００１を含む、請求項１〜３のいずれか一項に記載の組合せ物。
- １〜２０ｍｇのＢＥＺ２３５を含む、請求項１〜４のいずれか一項に記載の組合せ物。
- 前記被験体が免疫無防備状態である、請求項１〜５のいずれか一項に記載の組合せ物。
- 前記被験体が減損した免疫応答を有する、請求項１〜５のいずれか一項に記載の組合せ物。
- 前記被験体が免疫老化状態である、請求項１〜５のいずれか一項に記載の組合せ物。
- 加齢に関係する状態について前記被験体を処置するための、請求項１〜５のいずれか一項に記載の組合せ物。
- 前記加齢に関係する状態が、免疫老化、筋肉減少症、筋肉の消耗、腱の硬直、腱損傷、腱炎、アキレス腱断裂、肩の癒着性関節包炎、足底筋膜炎、リウマチ性多発筋痛、肩腱板断裂、脊柱管狭窄症、テニス肘、デュピュイトラン拘縮、不穏下肢症候群、骨粗鬆症、変形性関節症、関節リウマチ、自己免疫疾患、多発性筋炎、痛風、認知症、ハンチントン病、アルツハイマー病、脳委縮、加齢に関係する運動不能（例えば、虚弱）、認知機能低下、加齢に関係する認知症、記憶機能障害、レビー小体認知症、前頭側頭認知症、パーキンソン病、軽度認知機能障害、血管性認知症、脳卒中、一過性脳虚血発作、三叉神経痛、神経障害、睡眠障害、不眠症、アテローム性動脈硬化症、動脈硬化症、高血圧、心臓機能不全、例えば心肥大、収縮機能不全、または拡張機能不全、心不全、拡張型心筋症、駆出率が保たれた心不全、不整脈、心臓弁膜症、慢性閉塞性肺疾患、慢性閉塞性肺疾患増悪、肺気腫、特発性肺線維症、肺高血圧症、肺塞栓症、呼吸困難、ＮＡＳＨおよび肝硬変を含む肝疾患、胆石、腎結石、バレット食道、痔核、褥瘡性潰瘍、憩室炎、便秘、結腸ポリープ、痔核、便失禁、悪液質、吸収不全、***機能不全、***減退、白内障、加齢黄斑変性症、緑内障、網膜変性症、網膜剥離、ドライアイ、老視、転倒、めまい、良性前立腺肥大、前立腺がん、平均余命の短縮、減損した腎機能、慢性腎不全、急性腎不全、糸球体硬化症、糸球体硬化症、腎硬化症、脱水、神経因性膀胱、***症、膀胱炎、尿失禁、がん、肥満、メタボリック症候群、前糖尿病、糖尿病、皮膚萎縮症、皮膚老化、皺、脂漏性角化症、光線角化症、皮膚がん、日焼けで損傷を受けた皮膚、酒さ、爪甲真菌症、毛髪の白髪化、脱毛症、加齢性難聴、耳鳴症、嗅覚喪失、歯周疾患、虫歯、口内乾燥、甲状腺疾患、ミトコンドリアの機能不全と関連する疾患、ウェルナー症候群およびハッチンソンギルフォードプロジェリア症候群を含む早期老化症候群および早老症、貧血、葉酸欠乏性貧血、凝固障害、深部静脈血栓症、悪液質、うつ、ならびに平均余命の短縮からなる群より選択される、請求項９に記載の組合せ物。
- 請求項１〜５のいずれか一項に記載の組合せ物および少なくとも１種の薬学的に許容される担体を含む、医薬組成物。
- 被験体における免疫応答を促進または増強するための、請求項１〜５のいずれか一項に記載の組合せ物であって、前記組合せ物が、免疫応答を促進または増強するのに共同で治療上有効な量で投与されることを特徴とする、組合せ物。
- 加齢に関係する状態を有する被験体を処置するための、請求項１〜５のいずれか一項に記載の組合せ物であって、前記組合せ物が、前記加齢に関係する状態に対して共同で治療上有効な量で投与されることを特徴とする、組合せ物。
- 前記加齢に関係する状態が、免疫老化、筋肉減少症、筋肉の消耗、腱の硬直、腱損傷、腱炎、アキレス腱断裂、肩の癒着性関節包炎、足底筋膜炎、リウマチ性多発筋痛、肩腱板断裂、脊柱管狭窄症、テニス肘、デュピュイトラン拘縮、不穏下肢症候群、骨粗鬆症、変形性関節症、関節リウマチ、自己免疫疾患、多発性筋炎、痛風、認知症、ハンチントン病、アルツハイマー病、脳委縮、加齢に関係する運動不能（例えば、虚弱）、認知機能低下、加齢に関係する認知症、記憶機能障害、レビー小体認知症、前頭側頭認知症、パーキンソン病、軽度認知機能障害、血管性認知症、脳卒中、一過性脳虚血発作、三叉神経痛、神経障害、睡眠障害、不眠症、アテローム性動脈硬化症、動脈硬化症、高血圧、心臓機能不全、例えば心肥大、収縮機能不全、または拡張機能不全、心不全、拡張型心筋症、駆出率が保たれた心不全、不整脈、心臓弁膜症、慢性閉塞性肺疾患、慢性閉塞性肺疾患増悪、肺気腫、特発性肺線維症、肺高血圧症、肺塞栓症、呼吸困難、ＮＡＳＨおよび肝硬変を含む肝疾患、胆石、腎結石、バレット食道、痔核、褥瘡性潰瘍、憩室炎、便秘、結腸ポリープ、痔核、便失禁、悪液質、吸収不全、***機能不全、***減退、白内障、加齢黄斑変性症、緑内障、網膜変性症、網膜剥離、ドライアイ、老視、転倒、めまい、良性前立腺肥大、前立腺がん、平均余命の短縮、減損した腎機能、慢性腎不全、急性腎不全、糸球体硬化症、糸球体硬化症、腎硬化症、脱水、神経因性膀胱、***症、膀胱炎、尿失禁、がん、肥満、メタボリック症候群、前糖尿病、糖尿病、皮膚萎縮症、皮膚老化、皺、脂漏性角化症、光線角化症、皮膚がん、日焼けで損傷を受けた皮膚、酒さ、爪甲真菌症、毛髪の白髪化、脱毛症、加齢性難聴、耳鳴症、嗅覚喪失、歯周疾患、虫歯、口内乾燥、甲状腺疾患、ミトコンドリアの機能不全と関連する疾患、ウェルナー症候群およびハッチンソンギルフォードプロジェリア症候群を含む早期老化症候群および早老症、貧血、葉酸欠乏性貧血、凝固障害、深部静脈血栓症、悪液質、うつ、ならびに平均余命の短縮からなる群より選択される、請求項１３に記載の組合せ物。
- 約０．０１ｍｇ／日〜約１ｍｇ／日のＲＡＤ００１が投与されることを特徴とする、請求項１〜３のいずれか一項に記載の組合せ物。
- 約０．１ｍｇ／日のＲＡＤ００１が投与されることを特徴とする、請求項１〜５のいずれか一項に記載の組合せ物。
- 約１０ｍｇ／日のＢＥＺ２３５が投与されることを特徴とする、請求項１〜５のいずれか一項に記載の組合せ物。
- 投与が同時に行われる、請求項１〜５のいずれか一項に記載の組合せ物。
- 投与が別個に行われる、請求項１〜５のいずれか一項に記載の組合せ物。
- 約０．１ｍｇ／日のＲＡＤ００１が投与され、約１０ｍｇ／日のＢＥＺ２３５が投与されることを特徴とする、請求項１〜５のいずれか一項に記載の組合せ物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164354P | 2015-05-20 | 2015-05-20 | |
| US62/164,354 | 2015-05-20 | ||
| PCT/IB2016/052980 WO2016185443A1 (en) | 2015-05-20 | 2016-05-20 | Pharmaceutical combination of everolimus with dactolisib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520102A JP2018520102A (ja) | 2018-07-26 |
| JP2018520102A5 true JP2018520102A5 (ja) | 2019-06-20 |
| JP6857141B2 JP6857141B2 (ja) | 2021-04-14 |
Family
ID=57319542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560254A Active JP6857141B2 (ja) | 2015-05-20 | 2016-05-20 | エベロリムスとダクトリシブとの薬学的組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10576076B2 (ja) |
| EP (1) | EP3297629A1 (ja) |
| JP (1) | JP6857141B2 (ja) |
| KR (1) | KR20180058659A (ja) |
| CN (1) | CN107847491A (ja) |
| AU (1) | AU2016263176A1 (ja) |
| BR (1) | BR112017024732A2 (ja) |
| CA (1) | CA2986359A1 (ja) |
| EA (1) | EA201792314A1 (ja) |
| HK (1) | HK1245095A1 (ja) |
| IL (1) | IL255728A (ja) |
| MX (1) | MX2017014776A (ja) |
| WO (1) | WO2016185443A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11083725B2 (en) | 2014-10-24 | 2021-08-10 | St. Jude Children's Research Hospital | Coordinated metabolic reprogramming in response to productive viral infections |
| EP3297629A1 (en) | 2015-05-20 | 2018-03-28 | Novartis AG | Pharmaceutical combination of everolimus with dactolisib |
| EP3544608A1 (en) * | 2016-11-23 | 2019-10-02 | Novartis AG | Methods of enhancing immune response with everolimus, dactolisib or both |
| US11260078B2 (en) * | 2017-07-25 | 2022-03-01 | Insilico Medicine Ip Limited | Method of treating senescence with multi-stage longevity therapeutics |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
| CA2219659C (en) | 1995-06-09 | 2008-03-18 | Novartis Ag | Rapamycin derivatives |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| CA2230748C (en) | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| RU2214244C9 (ru) | 1998-03-26 | 2020-07-29 | Астеллас Фарма Инк. | Препараты с замедленным высвобождением |
| ES2219388T3 (es) | 1999-08-24 | 2004-12-01 | Ariad Gene Therapeutics, Inc. | 28-epi-rapalogos. |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| CN100522967C (zh) | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
| US20030203027A1 (en) | 2002-04-26 | 2003-10-30 | Ethicon, Inc. | Coating technique for deposition of drug substance on a substrate |
| US7075204B2 (en) | 2003-08-06 | 2006-07-11 | Honeywell International, Inc. | Threaded inner sleeve for generator magnet |
| AR045957A1 (es) | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| GB0419355D0 (en) | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| EP1858511A1 (en) | 2005-03-08 | 2007-11-28 | LifeCycle Pharma A/S | Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN103127100A (zh) | 2006-03-23 | 2013-06-05 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂和方法 |
| US20100266590A1 (en) | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
| EP1902708A1 (de) | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| US8436177B2 (en) | 2006-11-20 | 2013-05-07 | Novartis Ag | Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| KR101472607B1 (ko) | 2007-02-20 | 2014-12-15 | 노파르티스 아게 | 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린 |
| KR20100039354A (ko) | 2007-07-24 | 2010-04-15 | 노파르티스 아게 | Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 이미다조퀴놀린의 용도 |
| US20090082387A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| US20090088373A1 (en) | 2007-09-28 | 2009-04-02 | Gallo Richard L | Use of compositions to enhance innate immune response |
| JP2011513391A (ja) | 2008-03-05 | 2011-04-28 | パナセア バイオテック リミテッド | ミコフェノラートを含有する徐放性医薬組成物およびその方法 |
| BRPI0909082A2 (pt) | 2008-03-26 | 2019-02-26 | Novartis Ag | imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf |
| CA2733203A1 (en) | 2008-08-05 | 2010-02-11 | Emory University | Use of mtor inhibitors to enhance t cell immune responses |
| ES2899174T3 (es) | 2008-08-26 | 2022-03-10 | Hope City | Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T |
| EP2349275B1 (en) | 2008-10-31 | 2017-03-08 | Novartis AG | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor. |
| CA2937492C (en) | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| WO2010083298A1 (en) | 2009-01-14 | 2010-07-22 | Health Research Inc. | Methods and compositions containing mtor inhibitors for enhancing immune responses |
| US20100233733A1 (en) | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| MX2011010621A (es) | 2009-04-09 | 2012-01-30 | Alkermes Pharma Ireland Ltd | Composiciones de clozapina de liberacion controlada. |
| CN102612564B (zh) | 2009-04-10 | 2015-08-26 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
| CN101862297B (zh) | 2009-04-14 | 2012-07-25 | 上海医药工业研究院 | 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法 |
| US20120114637A1 (en) | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| TWI499592B (zh) | 2009-09-09 | 2015-09-11 | Avila Therapeutics Inc | Ｐｉ３激酶抑制劑及其用途 |
| CN102199152A (zh) | 2010-03-25 | 2011-09-28 | 高大新 | 杂环咪唑类磷脂激酶抑制剂 |
| WO2012006619A2 (en) | 2010-07-09 | 2012-01-12 | Northeastern University | ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS |
| AR083267A1 (es) | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| MX2013006187A (es) | 2010-12-03 | 2013-07-15 | Novartis Ag | Composiciones farmaceuticas. |
| LT2649086T (lt) | 2010-12-09 | 2017-11-10 | The Trustees Of The University Of Pennsylvania | Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui |
| US20140206678A1 (en) | 2011-01-27 | 2014-07-24 | Kadmon Corporation, Llc | Inhibitors of mtor kinase as anti -viral agent |
| EP2675450B1 (en) * | 2011-02-16 | 2016-02-10 | Novartis AG | Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases |
| CN102138903B (zh) | 2011-03-17 | 2012-12-12 | 苏州特瑞药业有限公司 | 一种依维莫司固体口服药物组合物 |
| US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| EA201490725A1 (ru) | 2011-09-30 | 2014-11-28 | Дана-Фарбер Кэнсер Инститьют, Инк. | Способ лечения мукоэпидермоидной карциномы |
| CN103874484B (zh) | 2011-10-06 | 2016-09-21 | 诺华股份有限公司 | 包含40-o-(2-羟基)乙基-雷帕霉素的药物组合物 |
| EP2638896A1 (en) | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| MX357823B (es) | 2012-04-11 | 2018-07-25 | Us Health | Receptores del antígeno quimérico que seleccionan el antígeno para la maduración de las células b. |
| BR112014030099A2 (pt) | 2012-06-06 | 2017-06-27 | Novartis Ag | combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor |
| US10799473B2 (en) | 2013-03-04 | 2020-10-13 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence |
| TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| AU2014273490B2 (en) | 2013-05-29 | 2019-05-09 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system |
| KR101582264B1 (ko) | 2013-06-27 | 2016-01-04 | 삼성전자 주식회사 | 유기 박막용 조성물, 유기 박막 및 상기 유기 박막을 포함하는 전자 소자 |
| KR20160084438A (ko) | 2013-11-13 | 2016-07-13 | 노파르티스 아게 | 면역 반응을 강화하기 위한 mTOR 억제제 |
| RS61406B1 (sr) | 2014-06-06 | 2021-03-31 | Bluebird Bio Inc | Poboljšane kompozicije t ćelija |
| EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
| MX2017001013A (es) | 2014-07-21 | 2018-02-21 | Novartis Ag | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| US20170274014A1 (en) | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
| HUE049218T2 (hu) | 2014-08-19 | 2020-10-28 | Novartis Ag | Anti-CD123 kiméra antigénreceptor (CAR) rák kezelésében történõ alkalmazásra |
| US11083725B2 (en) | 2014-10-24 | 2021-08-10 | St. Jude Children's Research Hospital | Coordinated metabolic reprogramming in response to productive viral infections |
| WO2016079332A1 (en) | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for improving immunotherapy |
| EP3297629A1 (en) | 2015-05-20 | 2018-03-28 | Novartis AG | Pharmaceutical combination of everolimus with dactolisib |
-
2016
- 2016-05-20 EP EP16725601.5A patent/EP3297629A1/en not_active Ceased
- 2016-05-20 CN CN201680039501.8A patent/CN107847491A/zh active Pending
- 2016-05-20 US US15/575,703 patent/US10576076B2/en not_active Expired - Fee Related
- 2016-05-20 KR KR1020177036823A patent/KR20180058659A/ko not_active Application Discontinuation
- 2016-05-20 CA CA2986359A patent/CA2986359A1/en not_active Abandoned
- 2016-05-20 EA EA201792314A patent/EA201792314A1/ru unknown
- 2016-05-20 WO PCT/IB2016/052980 patent/WO2016185443A1/en active Application Filing
- 2016-05-20 MX MX2017014776A patent/MX2017014776A/es unknown
- 2016-05-20 BR BR112017024732A patent/BR112017024732A2/pt not_active Application Discontinuation
- 2016-05-20 JP JP2017560254A patent/JP6857141B2/ja active Active
- 2016-05-20 AU AU2016263176A patent/AU2016263176A1/en not_active Abandoned
-
2017
- 2017-11-16 IL IL255728A patent/IL255728A/en unknown
-
2018
- 2018-04-04 HK HK18104516.7A patent/HK1245095A1/zh unknown
-
2019
- 2019-11-21 US US16/690,211 patent/US20210030741A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520102A5 (ja) | ||
| JP2019059760A5 (ja) | ||
| CN103945848B (zh) | 被取代的喹唑啉酮的口服即释制剂 | |
| JP2017222722A5 (ja) | ||
| ECSP055768A (es) | Derivados de azol-pirimidina condensados | |
| RU2019135834A (ru) | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила | |
| NO20075354L (no) | Forbindelser, isomerer og farmasoytiske akseptable salter derav, som vanilloidreseptorantagoniser, og farmasoytiske preparater inneholdende slike | |
| FI3833348T3 (fi) | Transglutaminaasi 2:n (tg2) inhibiittoreita | |
| JP2017531033A5 (ja) | ||
| JP2014139255A5 (ja) | ||
| PE20212111A1 (es) | Moduladores calpaina y usos terapeuticos de los mismos | |
| JP2023076632A5 (ja) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| MX2017015192A (es) | Derivado de bisamida de acido dicarboxilico como agente que estimula regeneracion de tejidos y recuperacion de funcion tisular disminuida. | |
| WO2020128816A3 (en) | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | |
| DE602005020178D1 (de) | 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten | |
| JP2018505218A5 (ja) | ||
| FI3484475T3 (fi) | 1-metyylinikotiiniamidi sydän- ja verisuonitautien hoitoon | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| EA202092763A1 (ru) | Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных | |
| RU2016136666A (ru) | Составы на основе прогестерона | |
| EA202092760A1 (ru) | Композиция афродизиака и терапия мужской сексуальной дисфункции | |
| EA202192111A1 (ru) | Новые тритерпеновые производные в качестве ингибиторов вич | |
| RU2015127345A (ru) | Способ лечения приобретенной эквино-варусной деформации стопы у детей с ДЦП |